Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density||
||412||Female||up to 80 Years (Child, Adult, Senior)||NCT00043186||20010223||May 2002||April 2007||June 2007||August 7, 2002||September 18, 2013||July 28, 2010|
|2||NCT03293108||Recruiting||Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Dyenix) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women||
||190||Female||45 Years to 75 Years (Adult, Senior)||NCT03293108||DEN.ARY.AJ.95 (III)||April 29, 2017||December 20, 2019||December 20, 2019||September 26, 2017||September 26, 2017||